Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Colorectal Neoplasms 5Rectal Neoplasms 2Cholangiocarcinoma 2Adenocarcinoma Of Esophagus 2Stomach Neoplasms 1Gallbladder Neoplasms 1Esophageal Neoplasms 1Disease Progression 1Colonic Neoplasms 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Bile Duct Neoplasms 1Advanced Rectal Cancer 1

Interventions

Fluorouracil 7Oxaliplatin 6Nivolumab 5Leucovorin 5fludarabine 4Cyclophosphamide 4Capecitabine 4zimberelimab 3pembrolizumab 3aldesleukin 3Trastuzumab 3Paclitaxel 3Docetaxel 3ulixertinib 2trastuzumab deruxtecan 2fludarabine phosphate 2Specimen Handling 2Ramucirumab 2Irinotecan 2zolbetuximab 1zanidatamab 1trifluridine tipiracil drug combination 1trastuzumab biosimilar HLX02 1trametinib 1tislelizumab 1sodium propionate 1sapanisertib 1relatlimab 1quemliclustat 1propionic acid 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Stomach Neoplasms × Folfox protocol × 30 days × Clear all
NCT07221149 2026-06-04

A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)

Bristol-Myers Squibb

Phase 2/3 Recruiting
690 enrolled
Gastrointestinal

Adenocarcinoma Of Esophagus, Stomach Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡